Galderma

Chinese National Medical Products Administration has approved our next-generation anti-wrinkle treatment, designed with PEARL™ Technology, for the improvement of frown lines in adults. This approval underscores Galderma’s continued leadership and further expands the global reach of our innovative anti-wrinkle solution. Learn more: https://lnkd.in/e8uKVgRp #AdvancingDermatology #SkinSciencebyGalderma #ForInvestors

We are pleased to report a record performance for the first nine months of the year, reflecting continued strong momentum across the business. Galderma delivered net sales of 4.765 billion USD, representing 25.1% year-on-year growth at constant currency. This strong performance was driven by broad-based, double-digit growth across geographies and categories, reflecting the continued execution of our integrated dermatology strategy. With this stronger-than-anticipated trajectory, we are raising our full-year net sales growth guidance to 22.5–23.5%. Thank you to our teams and partners around the world for their dedication and strong execution. Read more: https://lnkd.in/ezAgrP9G #AdvancingDermatology #Q3results #GALD

#ForInvestors This morning, we announced Galderma’s sales numbers for the first nine months of 2026, and I’m pleased to say they confirm the strength of our business momentum, and of our Integrated Dermatology Strategy. Net sales neared 4.8 billion USD, a record for the period and up 25.1% year-on-year at constant currency. This included a 13.2% increase in our Injectable Aesthetics business, a 16.2% rise in Dermatological Skincare, and a rise of 64.4% in Therapeutic Dermatology. Given these numbers and our confidence in the business, we have raised Galderma’s full-year 2026 net sales guidance to 22.5-23.5% year-on-year at constant currency and confirmed Core EBITDA margin of approximately 26% at constant currency. These results reflect, among other things, our success in keeping up the strong momentum of our novel biologic for atopic dermatitis and prurigo nodularis, whose net sales totaled 735 million USD in the first nine months of 2026, and of our new next-generation neuromodulator, now approved in 37 countries. We’ve also continued to deliver exciting innovations in both Cetaphil and Alastin, and I’m excited about the opportunities that the planned acquisition of ZO Skin Health will bring for the business, and for Galderma as a whole. A heartfelt thanks to everyone who is contributing to this performance and supporting our ambition to become an undisputed dermatology powerhouse. Read more: https://lnkd.in/eZhwDqqN #AdvancingDermatology #GaldermaGrowth

This World Menopause Day, we’re shedding a light on the impact this transition has on the skin – and the solutions available. In this video, Rosie and Anna share their experiences navigating menopause. Their stories reflect those of many women. A recent Galderma survey of 4,300 women across five continents found that many reported feeling less confident (55%), less attractive (60%) and less inclined to socialize (46%) as a result of menopause-related skin changes. At Galderma, we believe women should feel informed, confident and supported throughout every stage of their menopause journey. We're committed to closing the menopause knowledge gap – so women like Rosie and Anna are aware of the solutions available to them. Learn more about how we’re improving women’s wellbeing during menopause: https://lnkd.in/eiet4iDj #AdvancingDermatology #menopause

At AMWC Dubai 2026, Galderma is showcasing its leadership in Injectable Aesthetics, with data across its comprehensive portfolio. With eight abstracts, a symposium, and Meet-the-Expert sessions, we are highlighting innovation that addresses growing needs; from menopause-related skin changes and regenerative aesthetic solutions, to body indications. Discover how Galderma is advancing the science of aesthetics through evidence-based solutions that support complex patient profiles and unmet needs. Read more: https://lnkd.in/ei9kQJgb #AdvancingDermatology #SkinSciencebyGalderma #AMWCDubai

This week at AMWC in Dubai, from 21 to 23 October, Galderma is presenting eight scientific abstracts spanning our injectable aesthetics portfolio, alongside a symposium and six Meet-the-Expert sessions. The congress follows the recent approval in the UAE Sculptra for use on the body including the gluteal area, posterior thighs and décolletage. An international consensus panel of 11 experts will present guidance on combining treatments across these new indications. We will also share pooled phase III data for relabotulinumtoxinA in frown lines and crows feet, in both toxin-naïve and previously treated patients. Alongside the clinical data, we will present findings from our survey of more than 4,300 women across nine countries on menopause-related skin changes. As always, we have a powerful range of information to share -- all part of our journey towards becoming a dermatology powerhouse. At Galderma we firmly believe that progress in aesthetics is guided by science, experience and thoughtful clinical judgment, and that is the spirit we bring to Dubai, as we continue to build a dermatology powerhouse. #Galderma #DermatologyPowerhouse #InjectableAesthetics #AMWCDubai